Good morning, @sonieaml. The FLT3 mutation is a mutation that can be a challenge to wrestle into compliance. That was one of my mutations as well. Because of the FLT3 (pronounced as flit-3) my chemotherapy treatments were complimented with Midostaurin (RYDAPT) which is a drug targeting the FLT3 mutation.
What makes the FLT3 mutation difficult, the way it was explained to me, is basically that the mutation causes some of the cancer cells to evade chemotherapy by going ‘dormant’ during treatment only to emerge later and it can also allow some of the cells to learn ways to circumvent the chemo, making chemo less effective over time. The Midostaurin is an FLT3 inhibitor.
When you have your consult with your hematologist oncologist to discuss your BMB results you might want to ask what other treatment options are available if you’re not in remission. Ask about Midostaurin. It may not be appropriate for your case but since you have the FLT3 mutation it wouldn’t hurt to ask.
I’m here for you any time if you have questions or concerns. Will you let me know what you find out from your biopsy, please?